Neurizon Therapeutics Limited · ASX:NUZ

Neurizon Therapeutics — Shareholder Meeting (February 2026)

8 slides from Neurizon Therapeutics's shareholder meeting presentation, Feb 20, 2026

  1. Slide 1: General Meeting Presentation

    For personal use only General Meeting Presentation Dr Michael Thurn, Managing Director & Chief Executive Officer ASX|NUZ 20 February 2026 ABN 35 094 006 023

  2. Slide 2: Disclaimer

    Disclaimer For personal use only This disclaimer applies to this presentation and the information contained in it (This presentation has been Future Matters prepared by Neurizon Therapeutics Limited (ASX: NUZ) (the “Company”)). It does not purport to contain all the information that a prospective in

  3. Slide 3: Our Mission

    For personal use only Our Mission Advancing groundbreaking science to reach a promising new horizon in treatments for people living with ALS and other neurodegenerative diseases.

  4. Slide 4: Demonstrating Meaningful Progress

    Demonstrating Meaningful Progress For personal use only Executed Global NUZ-001 accepted Successful Secured registered Promising Australian License as the Regimen “I” manufacture of trademark exploratory top- Patent granted Agreement with in the HEALEY ALS three registration protection for line resu

  5. Slide 5: Funding Strategy

    Funding Strategy Strong shareholder support reinforces confidence in Neurizon’s strategy and long-term vision Neurizon’s funding has been strongly supported by its existing shareholders and has allowed the company to commit to the HEALEY For personal use only ALS Platform Trial. The strategy is focu

  6. Slide 6: 'Regimen-I' HEALEY ALS Platform Trial Expected Key Milestones

    ‘Regimen-I’ HEALEY ALS Platform Trial Expected Key Milestones Q4 2025 Q4 2025 Q1 2026 Q1 2026 Q3-Q4 2026 Q2-Q3 2027 Q3 2027 Q3 2027 For personal use only 3 4 5 6 7 8 IND Amendment FDA First Patient First Patient Enrollment Last Patient Database Topline Data Submission Clearance Screened Randomized C

  7. Slide 7: Near-Term Milestones and Objectives

    Near-Term Milestones Objectives For personal use only  HEALEY ALS Platform Trial– IRB Approval •Ethics Approval for Liquid Formulation PK Study 44 th J.P. Morgan Annual Healthcare Conference and other • Preclinical Updates events • HEALEY Updates Australian R&D Refund (net of R&D funding) • Liqui

  8. Slide 8: Registered Address

    For personal use only Registered Address: Suite 2, Level 11, 385 Bourke Street Melbourne VIC 3000 Australia +61 (3) 9692 7222 enquiries@neurizon.com

Neurizon Therapeutics — Shareholder Meeting (February 2026) on 6ix